Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06930638 · ClinicalTrials.gov registry record · Phase 2
MitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes
A Phase 2 study of Stroke, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06930638: Recruiting Phase 2 study of Stroke, sponsored by Medical College of Wisconsin.
NCT06930638 is a Phase 2 study of Stroke that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 30 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06930638, a Phase 2 study of Stroke, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows a single bout of ischemic conditioning or oral ingestion of an over-the-counter antioxidant supplement called MitoQ may improve vascular function and muscle activity in individuals post-stroke.
Primary Outcome
We will measure brachial artery vascular health in the non-paretic arm. Baseline brachial artery diameter and blood flow velocity through the artery will be measured before and after a pneumatic forearm cuff is inflated to 225 mmHg for five minutes.
Conditions Studied
Interventions
- DEVICE Ischemic Conditioning
- DIETARY_SUPPLEMENT Antioxidant Supplement
Study Locations (1)
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-07-22 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT06930638 shows while recruiting
NCT06930638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Ischemic Conditioning is the first listed.
NCT06930638 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06930638 about?
NCT06930638 is a clinical study titled "MitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes". Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows a single bout of ischemic conditioning or oral ingestion of an over-the-counter antioxidant supplement called Mito...
What is the current status of trial NCT06930638?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-07-22. Estimated completion is 2026-12-31.
What conditions does trial NCT06930638 study?
This clinical trial studies the following conditions: Stroke.
What interventions are being tested in trial NCT06930638?
The interventions under investigation include: Ischemic Conditioning (DEVICE), Antioxidant Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06930638?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06930638 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06930638's enrollment target sits among peer trials
30 301st of 454 higher than 137 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia
RECRUITING · Phase 2
-
Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia
RECRUITING · Phase 2
-
Myofascial Dysfunction in Post Stroke Shoulder Pain
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI